Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Battle of the bacteria busters: triple vs quadruple therapy for stomach bug

NCT ID NCT07010744

Disease control Sponsor: Akil Al Islam Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two different drug combinations to treat Helicobacter pylori, a stomach bacteria that can cause indigestion. About 66 adults with dyspepsia will receive either a triple therapy (amoxicillin, clarithromycin, esomeprazole) or a quadruple therapy (bismuth, metronidazole, tetracycline, esomeprazole) for 14 days. Researchers will check which treatment clears the infection better and track any side effects reported by patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Amoxicillin, Clarithromycin, Esomeprazole (triple therapy) vs Bismuth subcitrate, Metronidazole, Tetracycline, Esomeprazole (quadruple therapy)
What this could lead to
If successful, this could show which treatment is more effective at clearing H. pylori infection, helping doctors choose the best option for patients.
What could go wrong
This is a small, early-stage trial with only 66 participants, so results may not apply to everyone. Side effects from the drugs are possible, and the study may not find a clear winner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All dyspeptic patients aged ≥18 years. * Patients who will provide informed written consent and agree to follow-up at 4 weeks post-treatment. Exclusion Criteria: * Patients who have received prior H. pylori eradication therapy. * Ingestion of antibiotics or proton pump inhibitor within the prior 4 weeks. Patient who will test negative either of CLO or Stool Antigen Test or both * Patients with known allergies or intolerance to any of the study medications. * Patients with alarm symptoms (e.g., unexplained weight loss, persistent vomiting, dysphagia). * Patients with a history of gastric surgery. * Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyspepsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dyspepsia Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyspepsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dhaka Medical College

    Dhaka, 1000, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.